Get the Stockscreener App
5.82
2.80%
-0.17
An 2 Therapeutics Inc stock is traded at $5.82, with a volume of 221.54K.
It is down -2.80% in the last 24 hours and up +24.41% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
See More
Previous Close:
$5.99
Open:
$5.96
24h Volume:
221.54K
Relative Volume:
0.77
Market Cap:
$219.44M
Revenue:
-
Net Income/Loss:
$-34.55M
P/E Ratio:
-5.2698
EPS:
-1.1044
Net Cash Flow:
$-31.28M
1W Performance:
-1.48%
1M Performance:
+24.41%
6M Performance:
+454.51%
1Y Performance:
+444.15%
1-Day Range:
$5.765
$6.21
1-Week Range:
$5.66
$7.19
52-Week Range:
$1.00
$7.19
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
5.815 | 226.04M | 0 | -34.55M | -31.28M | -1.1044 |
VRTX
Vertex Pharmaceuticals Inc
|
515.76 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.65 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.87 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.83 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in SchizophreniaSlideshow (NASDAQ:MPLT) 2026-07-28 - Seeking Alpha
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - GlobeNewswire
Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn - The Hindu
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Yahoo Finance
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis - GlobeNewswire
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of - GlobeNewswire
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know - Yahoo Finance
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Nuo Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Apogee Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Oncotelic Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Intellia Therapeutics, Inc. SEC Filing (Jul 2, 2026) - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - BioSpace
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress - Business Wire
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data - StocksToTrade
BioRestorative Therapies Announces Completion of BRTX-100 - GlobeNewswire
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades - StocksToTrade
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewswire
TG Therapeutics Announces Positive Topline Phase 1 Data for - GlobeNewswire
Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron - Yahoo Finance
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement - TradingKey
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
An 2 Therapeutics Inc Stock (ANTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Williams Sarah Joanne | Principal Accounting Officer |
May 29 '26 |
Sale |
4.43 |
265 |
1,174 |
66,583 |
| Williams Sarah Joanne | Principal Accounting Officer |
Mar 03 '26 |
Sale |
1.06 |
327 |
347 |
66,848 |
| Day Lucy | Chief Financial Officer |
Jan 06 '26 |
Sale |
1.01 |
5,512 |
5,578 |
75,363 |
| Day Lucy | Chief Financial Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
80,875 |
| Prior Stephen David | Chief Strategy Officer |
Jan 05 '26 |
Sale |
1.00 |
3,604 |
3,615 |
61,944 |
| Prior Stephen David | Chief Strategy Officer |
Jan 06 '26 |
Sale |
1.01 |
2,858 |
2,892 |
59,086 |
| Chanda Sanjay | Chief Development Officer |
Jan 06 '26 |
Sale |
1.01 |
5,956 |
6,027 |
75,823 |
| Chanda Sanjay | Chief Development Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
81,779 |
| Eizen Joshua M | See Remarks |
Jan 05 '26 |
Sale |
1.00 |
17,923 |
17,948 |
159,430 |
| Eizen Joshua M | See Remarks |
Jan 06 '26 |
Sale |
1.01 |
6,931 |
7,014 |
152,499 |
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):